162 related articles for article (PubMed ID: 32674095)
1. Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
Kotake M; Kuwako T; Imai H; Tomizawa Y; Kaira K; Yoshii A; Ochiai M; Miura Y; Osaki T; Sakurai R; Takei K; Minato K; Saito R
Chemotherapy; 2020; 65(1-2):21-28. PubMed ID: 32674095
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.
Anzai M; Morikawa M; Okuno T; Umeda Y; Demura Y; Sonoda T; Yamaguchi M; Kanno K; Shiozaki K; Ameshima S; Akai M; Ishizuka T
Medicine (Baltimore); 2017 Dec; 96(51):e9320. PubMed ID: 29390506
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H
Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
5. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T
Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
Yoshimura N; Sawa K; Nakai T; Matsumoto Y; Mitsuoka S; Kimura T; Asai K; Yana T; Kawaguchi T; Hirata K
Am J Clin Oncol; 2021 Dec; 44(12):613-618. PubMed ID: 34753884
[TBL] [Abstract][Full Text] [Related]
7. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M
BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.
Sonoda T; Umeda Y; Demura Y; Tada T; Nakashima K; Anzai M; Yamaguchi M; Shimada A; Ohi M; Honjo C; Waseda Y; Akai M; Ishizuka T
Cancer Med; 2023 Jun; 12(12):13041-13053. PubMed ID: 37081729
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Chihara Y; Yoshimura A; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Takeuchi M; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
Oncologist; 2019 Aug; 24(8):1033-e617. PubMed ID: 31040252
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
15. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
[TBL] [Abstract][Full Text] [Related]
17. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
Jin F; Zhu H; Shi F; Kong L; Yu J
Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
[TBL] [Abstract][Full Text] [Related]
19. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
